Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 320

1.

Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.

Taşkın S, Güngör M, Ortaç F, Öztuna D.

Arch Gynecol Obstet. 2013 Dec;288(6):1399-403. doi: 10.1007/s00404-013-2924-7. Epub 2013 Jun 18.

PMID:
23775264
2.

Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.

da Costa Miranda V, de Souza Fêde ÂB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez Diz M.

Gynecol Oncol. 2014 Feb;132(2):287-91. doi: 10.1016/j.ygyno.2013.12.002. Epub 2013 Dec 9.

PMID:
24333355
3.

Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).

Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi DA, Santin AD, Schwartz PE.

J Surg Oncol. 2013 Feb;107(2):195-200. doi: 10.1002/jso.23171. Epub 2012 May 30.

PMID:
22648987
4.

Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?

Markauskas A, Mogensen O, dePont Christensen R, Jensen PT.

Int J Gynecol Cancer. 2014 Oct;24(8):1420-8. doi: 10.1097/IGC.0000000000000241.

PMID:
25180461
5.

Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A Single-Institution Experience and a Review of the Literature.

Loizzi V, Leone L, Camporeale A, Resta L, Selvaggi L, Cicinelli E, Cormio G.

Oncology. 2016;91(4):211-216. Epub 2016 Aug 3. Review.

PMID:
27487241
6.

Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.

Fagö-Olsen CL, Ottesen B, Kehlet H, Antonsen SL, Christensen IJ, Markauskas A, Mosgaard BJ, Ottosen C, Soegaard CH, Soegaard-Andersen E, Hoegdall C.

Gynecol Oncol. 2014 Feb;132(2):292-8. doi: 10.1016/j.ygyno.2013.11.035. Epub 2013 Dec 7.

PMID:
24321400
7.

Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.

Petrillo M, Zannoni GF, Tortorella L, Pedone Anchora L, Salutari V, Ercoli A, Margariti PA, Scambia G, Fagotti A.

Am J Obstet Gynecol. 2014 Dec;211(6):632.e1-8. doi: 10.1016/j.ajog.2014.06.034. Epub 2014 Jun 19.

PMID:
24954656
8.

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Chi DS, Musa F, Dao F, Zivanovic O, Sonoda Y, Leitao MM, Levine DA, Gardner GJ, Abu-Rustum NR, Barakat RR.

Gynecol Oncol. 2012 Jan;124(1):10-4. doi: 10.1016/j.ygyno.2011.08.014. Epub 2011 Sep 13.

PMID:
21917306
9.

[Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].

Ma Y, Li Y, Cui H, Liang XD, Tang ZJ, Li XP, Zhao Y, Wei LH.

Zhonghua Fu Chan Ke Za Zhi. 2012 May;47(5):355-60. Chinese.

PMID:
22883524
10.

Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.

Rauh-Hain JA, Rodriguez N, Growdon WB, Goodman AK, Boruta DM 2nd, Horowitz NS, del Carmen MG, Schorge JO.

Ann Surg Oncol. 2012 Mar;19(3):959-65. doi: 10.1245/s10434-011-2100-x. Epub 2011 Oct 13.

PMID:
21994038
11.

Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study.

Loizzi V, Cormio G, Resta L, Rossi CA, Di Gilio AR, Cuccovillo A, Selvaggi L.

Int J Gynecol Cancer. 2005 Mar-Apr;15(2):217-23.

PMID:
15823102
12.

Neoadjuvant chemotherapy followed by surgical cytoreduction in advanced epithelial ovarian cancer.

Deo SV, Goyal H, Shukla NK, Raina V, Kumar L, Srinivas G.

Indian J Cancer. 2006 Jul-Sep;43(3):117-21.

13.

Clinical outcome of Iranian patients with advanced ovarian cancer with neoadjuvant chemotherapy versus primary debulking surgery.

Ghaemmaghami F, Karimi-Zarchi M, Modares-Gilani M, Mousavi A, Behtash N.

Asian Pac J Cancer Prev. 2008 Oct-Dec;9(4):719-24.

14.

Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy.

Greimel E, Kristensen GB, van der Burg ME, Coronado P, Rustin G, del Rio AS, Reed NS, Nordal RR, Coens C, Vergote I; European Organization for Research and Treatment of Cancer - Gynaecological Cancer Group and NCIC Clinical Trials Group.

Gynecol Oncol. 2013 Nov;131(2):437-44. doi: 10.1016/j.ygyno.2013.08.014. Epub 2013 Aug 27.

PMID:
23994107
15.

Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.

Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, Bradford LS, Berkowitz RS, Schorge JO, Campos SM, del Carmen MG, Horowitz NS.

Gynecol Oncol. 2013 Apr;129(1):63-8. doi: 10.1016/j.ygyno.2013.01.009. Epub 2013 Jan 18.

PMID:
23337490
16.

TP53 K351N mutation-associated platinum resistance after neoadjuvant chemotherapy in patients with advanced ovarian cancer.

Zhang GN, Liu H, Huang JM, Wang L, Zhao JS, Li C, Mi K, Zhu Y, Cheng J, Zha X.

Gynecol Oncol. 2014 Mar;132(3):752-7. doi: 10.1016/j.ygyno.2014.01.028. Epub 2014 Jan 23.

PMID:
24463159
17.

Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.

Vergote I, Amant F, Kristensen G, Ehlen T, Reed NS, Casado A.

Eur J Cancer. 2011 Sep;47 Suppl 3:S88-92. doi: 10.1016/S0959-8049(11)70152-6. Review.

PMID:
21944035
18.

Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.

Muraji M, Sudo T, Iwasaki S, Ueno S, Wakahashi S, Yamaguchi S, Fujiwara K, Nishimura R.

Gynecol Oncol. 2013 Dec;131(3):531-4. doi: 10.1016/j.ygyno.2013.09.030. Epub 2013 Oct 4.

PMID:
24096109
19.

Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.

Gill SE, McGree ME, Weaver AL, Cliby WA, Langstraat CL.

Gynecol Oncol. 2017 Feb;144(2):266-273. doi: 10.1016/j.ygyno.2016.11.021. Epub 2016 Dec 1.

PMID:
27916269
20.

Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.

Favero G, Macerox N, Pfiffer T, Köhler C, da Costa Miranda V, Estevez Diz Mdel P, Fukushima JT, Baracat EC, Carvalho JP.

Oncology. 2015;89(3):159-66. doi: 10.1159/000381462. Epub 2015 May 1.

PMID:
25968072

Supplemental Content

Support Center